LXEO
NASDAQ · Biotechnology
Lexeo Therapeutics Inc
$5.52
-0.02 (-0.36%)
Open$5.39
Previous Close$5.54
Day High$5.57
Day Low$5.22
52W High$10.99
52W Low$1.45
Volume—
Avg Volume566.6K
Market Cap478.80M
P/E Ratio—
EPS$-2.70
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+741.8% upside
Current
$5.52
$5.52
Target
$46.47
$46.47
$27.16
$46.47 avg
$57.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 110.56M | 98.68M | 97.87M |
| Net Income | 17.37M | 14.67M | 15.60M |
| Profit Margin | 15.7% | 14.9% | 15.9% |
| EBITDA | 19.93M | 19.03M | 18.02M |
| Free Cash Flow | 11.85M | 8.63M | 11.57M |
| Rev Growth | +16.0% | -2.8% | +7.5% |
| Debt/Equity | 0.49 | 0.46 | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |